canakinumab Archives -

Expectations for Novartis’ canakinumab as an oncology therapy were already fading fast, and have now been nixed after

Strike three for Novartis’ canakinumab as lung cancer therapy

https://pharmaphorum.com/news/strike-three-for-novartis-canakinumab-as-lung-cancer-therapy/

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3

Strike two for Novartis’ lung cancer antibody canakinumab

https://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/

Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless

Novartis’ canakinumab falls short in phase 3 lung cancer trial

https://pharmaphorum.com/news/novartis-canakinumab-falls-short-in-phase-3-lung-cancer-trial/

canakinumab